

Influenza Reagent Influenza virus infectious X-273 NIBSC code: 16/268 Instructions for use (Version 3.0, Dated 26/10/2016)

1. INTENDED USE

Reagent 16/268 is prepared from X-273 (A/Norway/2178/2014 x A/PR/8/34) which was processed for freeze drying in 250µl volumes as described by Campbell, PJ, Journal of Biological Standardisation, 1974, 2,249-267. The derivation and known passage history of X-273 is attached

2. CAUTION

This preparation is not for administration to humans or animals in the human food chain.

The material is not of human or bovine origin. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE

No unitage is assigned to this material

4. CONTENTS

Country of origin of biological material: United Kingdom. Each ampoule contains 250µl (nominal) of infectious influenza virus as allantoic fluid from SPF embryonated hen's eggs.

5. STORAGE

Store in the dark at -20°C or below

Please note: because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.

DIRECTIONS FOR OPENING

DIN ampoules have an 'easy-open' coloured stress point, where the narrow ampoule stem joins the wider ampoule body. Various types of ampoule breaker are available commercially. To open the ampoule, tap the ampoule gently to collect material at the bottom (labelled) end and follow manufactures instructions provided with the ampoule breaker.

7. USE OF MATERIAL

Reconstitute the contents of one ampoule of reagent with 250µl of sterile distilled water. Leave for a minimum of 5 minutes before use to allow for complete solution of freeze-dried material. A range of dilutions (e.g. 10⁻³ to 10⁻⁵) should be made in a suitable medium for initial cultivation.

8. STABILITY

Reference Materials should be stored on receipt as indicated on the

NIBSC follows the policy of WHO with respect to its reference materials.

REFERENCES

NA

ACKNOWLEDGEMENTS 10.

NA

National Institute for Biological Standards and Control,

Potters Bar, Hertfordshire, EN6 3QG. T +44 (0)1707 641000, nibsc.org WHO International Laboratory for Biological Standards, **UK Official Medicines Control Laboratory**

11. FURTHER INFORMATION

Further information can be obtained as follows:

This material: enquiries@nibsc.org

WHO Biological Standards:

http://www.who.int/biologicals/en/

JCTLM Higher order reference materials: http://www.bipm.org/en/committees/jc/jctlm/

Derivation of International Units:

http://www.nibsc.org/standardisation/international_standards.aspx Ordering standards from NIBSC:

http://www.nibsc.org/products/ordering.aspx

NIBSC Terms & Conditions:

http://www.nibsc.org/terms_and_conditions.aspx

12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited

14. MATERIAL SAFETY SHEET

Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

No 12/2/2008. Not applicable of not classified						
Physical and Chemical properties						
Physical appearance:			Corrosive:	No		
white powder						
Stable:	Yes		Oxidising:	No		
Hygroscopic:	No		Irritant:	No		
Flammable:	No		Handling:See	e caution, Section 2		
Other (specify): Live influenza virus						
Toxicological properties						
Effects of inhalation:		Likelihood of influenza virus infection				
Effects of ingestion:		Not established, avoid ingestion				
Effects of skin absorption:		Not established, avoid contact with skin				
Suggested First Aid						
Inhalation:	Seek r	Seek medical advice				
Ingestion: Seek medical advice						
Contact with eyes: Wash with copious amounts of water. Seek medical advice						
Contact with skin: Wash thoroughly with water.						
Action on Spillage and Method of Disposal						

Action on Spillage and Method of Disposal

Spillage of contents should be taken up with absorbent material wetted with an appropriate virucidal agent. Rinse area with an appropriate virucidal agent followed by water.

Absorbent materials used to treat spillage should be treated as biologically hazardous waste.

15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) ("Conditions") apply to the exclusion of all other



terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. INFORMATION FOR CUSTOMS USE ONLY

Country of origin for customs purposes*: United Kingdom

* Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.

Net weight: NA

Toxicity Statement: Non-toxic

Veterinary certificate or other statement if applicable.

Attached: No

Derivation of NYMC X-273 High Yield H3N2 Reassortant (5:3) with A/PR/8/34 PB1, PB2, PA, NS, and M genes and A/Norway/2178/2014 NP, HA, and NA genes

Experiment # 4776 (12/29/2015) A/Norway/2178/2014 (H3N2) Clone 37 E7 (Am3Al4) dil 10⁻⁵ GP 128-256 CL37 4/21/2015

Passages prior to receipt at NYMC -7


Passages at New York Medical College

Passage No.

1 10⁻³
<u>HA—1:16</u>

Reassortment passage at NYMC


A/Norway/2178/2014 (H3N2) x A/PR/8/34



National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, EN6 3QG. T +44 (0)1707 641000, nibsc.org

WHO International Laboratory for Biological Standards, UK Official Medicines Control Laboratory





NP, HA and NA genes were identified as A/Norway/2178/2014 by RT-PCR/RFLP gene analysis. PB2, PB1, PA, NS, and M genes were identified as A/PR/8/34 by RT-PCR/RFLP analysis.

SPF eggs were used for all reassortant passages.

All HA titers were tested using chicken red blood cells (cRBC) at room temperature.

Virus seed was shown to be sterile. Sterility testing was performed by streaking the sample on blood agar plates and incubating for 48 hours at 37 °C.

Passage history of X-273

Passage	Lot	Laboratory
E7/E9	E#6226	NYMC, USA
E7/E10	42220	NIBSC, Hertfordshire, UK

Sterility: No visible contamination was detected in a variety of media (tryptose soya broth, thioglycolate broth, Sabouraud's broth and blood agar plates) after 14 days incubation.

The HA and NA sequence of this virus is available on GISAID with the accession number EPI_ISL_235513



